Aldeyra Therapeutics, Inc.
ALDX
$1.52
-$0.03-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 44.20% | 65.23% | 59.13% | 49.13% | 42.03% |
| Total Depreciation and Amortization | 13.48% | 9.36% | 1.09% | 1.11% | 1.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,000.77% | -149.81% | 30.21% | -14.16% | -112.60% |
| Change in Net Operating Assets | -164.02% | 83.43% | -99.98% | -140.77% | -36.97% |
| Cash from Operations | 46.36% | 59.02% | 55.97% | 11.96% | 35.31% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1,123.08% | 375.05% | 96.96% |
| Cash from Investing | 95.83% | -- | 1,123.08% | 375.05% | 96.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -92.91% | -100.00% | 506.53% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -92.91% | -100.00% | 161.14% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -118.60% | -20.65% | 178.72% | 722.03% | 71.05% |